Using CB-839 to Inhibit GLS

Potency depends on glutamine concentration, so report both.

Mechanism and Concentration

CB-839 (telaglenastat) is a non-competitive, selective inhibitor of GLS1, with much lower potency against GLS2.

ConcentrationContextNote
0.1–0.5 µMCellular IC50 range in sensitive linesRequires sensitive readout
1 µMThe most commonly used concentrationAdequate in many lines
2–5 µMHigher end; used in resistant linesOff-target risk rises
Above 10 µMRarely justifiedNot a GLS-specific experiment

Caveat on potency variation. Cellular potency depends on glutamine concentration, because the inhibition is non-competitive with respect to glutamine but the pathway flux depends on substrate supply. In medium with 4 mM glutamine, a higher CB-839 concentration is needed to suppress flux than in medium with 1 mM. The concentration and the medium belong together.

Part 1 — Design

ParameterRecommendationWhy
Pre-incubation1–4 h before the assaySlower effect than a direct enzyme inhibitor
Glutamine concentrationState it; test at least twoDetermines the apparent potency
On-target controlGLS1 knockdown, or GLS2-expressing comparatorSpecificity
RescueCell-permeable α-KG (dimethyl-α-KG), nucleosides, NACWhich role mattered
ReadoutsGlutamate release, ¹³C-glutamine into TCA, growthFlux plus phenotype
Viability timepointEarly and lateSeparates metabolic from cytotoxic effects

The second row is the one that most often changes the result. A GLS dependency in 0.5 mM glutamine can disappear at 4 mM, because glutamate import and alternative anaplerosis become sufficient. Reporting one concentration without the other gives a result that does not generalise.

Part 2 — The α-Ketoglutarate Rescue and Its Problems

The logic is appealing: if GLS inhibition works by starving the TCA cycle of α-KG, then supplying α-KG should rescue. The execution is less clean.

IssueDetail
Permeabilityα-KG itself is poorly cell-permeable; the dimethyl ester is used
ConcentrationMillimolar concentrations are required, with osmotic and pH effects
MetabolismSupplied α-KG is metabolised, not inert; it can be oxidised or transaminated
AmmoniaSome α-KG preparations carry ammonium; check
Specificityα-KG can affect signalling (prolyl hydroxylases; epigenetic enzymes)

Readout note. A rescue with 4 mM dimethyl-α-KG that restores growth is consistent with anaplerotic rescue, but the concentration is high enough that osmotic and pH controls are required. A rescue at 1 mM that is partial is more interpretable and is worth trying first.

Part 3 — What the Inhibitor Does Not Tell You

  • • That GLS was the only affected step. Glutamate can be imported and can come from protein turnover.
  • • That anaplerosis was the relevant function. Nitrogen donation, glutathione synthesis and nucleotide synthesis are all GLS-dependent.
  • • That the effect is tumour-selective. Sensitivity varies with glutamine supply, GLS2 expression and alternative anaplerosis.
  • • That a growth effect is a viability effect. Growth arrest and death are different endpoints.

Part 4 — Model Requirements and Recurring Failures

RequirementWhy
Medium glutamine statedSets potency and dependency
Medium age recordedGlutamine degrades; ammonia accumulates
GLS1 and GLS2 statusDetermines inhibitor effect
Glutamate import consideredCan bypass the enzyme
Ammonia measuredProduct of the inhibited pathway
Viability and growth both measuredDifferent endpoints

Recurring failures:

  • • Single concentration, single medium, with the dependency generalised.
  • • No on-target control, so an off-target effect is indistinguishable.
  • • α-KG rescue without osmotic control.
  • • Growth reported as viability.
  • • Glutamate release not measured, so target engagement is unconfirmed.
  • • Medium age unrecorded, so glutamine depletion is attributed to the drug.

Part 5 — Interpreting a Negative Result

A line that does not respond to CB-839 is informative.

ExplanationTest
Glutamate import sufficientGlutamine-free and glutamate-free medium
Alternative anaplerosis (pyruvate carboxylase)Knockdown of PC or of the alternative route
Low GLS1 expressionMeasure GLS1; check GLS2
High glutamine mediumRepeat at 0.5–1 mM
Salvage of nitrogen from other sourcesSingle amino acid dropout panel

A negative result with these controls is a statement about the model's metabolic wiring, which is a useful result and is rarely reported as one.

If you need GLS dependency tested across glutamine concentrations with rescue and on-target controls, we can scope the design with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Potency, sensitivity and rescue requirements vary with cell type, glutamine concentration and alternative substrate availability. The concentrations here are starting points.

Inhibition of GLS does not establish which glutamine function was required, and growth arrest does not establish cell death.

Scientific interpretation and experimental design

  • • Potency depends on glutamine. Report both.
  • • Pre-incubate. The effect is not instantaneous.
  • • On-target control is mandatory. Knockdown, or GLS2 comparison.
  • • α-KG rescue has its own effects. Control osmolarity and pH.
  • • Glutamate release confirms engagement.
  • • A negative result can be the finding.

Selected references for further reading

  • • Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Molecular Cancer Therapeutics. 2014;13:890–901.
  • • Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nature Reviews Cancer. 2016;16:619–634.
  • • Biancur DE, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nature Communications. 2017;8:15965.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: